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Abstract: A sterically stabilized, mitoxantrone-loaded liposome, tailored to target luteinizing 
hormone-releasing  hormone  (LHRH)  receptor  overexpressing  cells,  was  developed  to 
promote the efficiency of intracellular delivery of mitoxantrone through receptor-mediated 
endocytosis. Liposomes were prepared by lipid film hydration and an ultrasound dispersion 
process. Thiolated gonadorelin with affinity for the LHRH receptor was chemically coupled 
to  N-[(3-maleimide-1-oxopropyl)  aminopropyl  polyethylene  glycol-carbamyl]  distearoyl-l-
phosphatidyl-ethanolamine via a thioether bond and subsequently inserted into polyethylene 
glycol-grafted liposomes. The liposome was characterized in terms of its size, ligand density, 
drug loading, and leakage properties. The targeting nature and antitumor effects of the liposomes 
were evaluated in vitro using cultured MCF-7 breast cancer cells. A protein assay of ligand 
coupling to the liposomal surface indicated that more than 60% of the LHRH peptides were 
inserted into the liposome bilayer. Up to 1.0 mg/mL of stable liposomal mitoxantrone loading 
was achieved, with approximately 98% of this being entrapped within the liposomes. In vitro 
cell culture studies revealed that the gonadorelin-modified liposomes bound to their target 
cells had significantly higher affinity and better antitumor efficiency than generic drug-loaded 
liposomes. These events were presumed to occur through specific interactions of the LHRH 
with its cognate receptors on the cell surface. It was concluded that the targeting properties 
of the delivery system would potentially improve the therapeutic benefits of mitoxantrone, as 
compared with nontargeted liposomes.
Keywords: mitoxantrone, liposome, luteinizing hormone-releasing hormone receptor, tumor 
targeting
Introduction
Chemotherapy is a common procedure for the treatment of advanced or metastatic 
cancer.1 However, the application of free anticancer drugs has several drawbacks, 
including lack of selectivity, toxicity to normal cells, rapid elimination from the 
circulation, and instigation of acquired or intrinsic multidrug resistance of cancer cells.2 
Targeted delivery of anticancer drugs to tumors may assist in resolving these issues. 
Currently, an attractive solution is based on the use of nanocarriers. Encapsulation 
of anticancer drugs within such carriers could minimize drug degradation, prevent 
undesirable side effects, and increase the fraction of the drug accumulated in the 
diseased tissue.
Liposomes represent one of the most efficient and well characterized drug delivery 
strategies for small molecules.3 These particles are biodegradable, biologically inert, 
have no antigenic or pyrogenic reactions, and possess limited intrinsic toxicity. International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Moreover, liposomes are better suited for drug targeting 
because of the ease of modifying their surface structure 
when compared with other drug carriers. Rationally designed 
liposomes, such as polyethylene glycol (PEG)-grafted 
liposomes (PEGylated liposomes), have the ability to accu-
mulate passively in tumor tissues via “leaky” vasculature 
through the enhanced permeability and retention effect.4 This 
passive accumulation can be further enhanced by actively 
targeting PEGylated liposomes to these tumor areas. Target-
ing of such liposomes could potentially reduce the extent of 
nonspecific toxicity associated with many drugs.
Targeting can be achieved by attaching a ligand for 
specific receptors that are expressed preferentially on 
tumor cells. Use of ligand-targeted liposomes has been 
demonstrated to result in increased internalization and 
more effective nuclear delivery of anticancer drugs, thus 
overcoming the problem of multiple drug resistance.5 The 
luteinizing hormone-releasing hormone (LHRH) receptor 
is characteristically overexpressed in many tumors, such as 
breast, ovarian, endometrial, prostate, hepatic, colorectal, and 
pancreatic cancers, renal cell carcinomas, nervous system 
tumors, oral and laryngeal carcinomas, and melanomas, but 
is barely expressed in healthy visceral organs.6–8 The elevated 
expression of LHRH receptors in various cancers makes it 
possible to use these receptors as target moieties to deliver 
cytotoxic agents.9 Analogs of LHRH have reportedly been 
used to deliver cytotoxic molecules to the tumor, and these 
cytotoxic analogs can be internalized by human ovarian 
and endometrial cancer cells10–12 and MCF-7 human breast 
cancer cells.13,14
Mitoxantrone, a synthetic anthraquinone drug, has high 
antitumor activity against acute nonlymphocytic leukemia, 
advanced breast cancer, and non-Hodgkin’s lymphomas. The 
dose-limiting toxicity associated with mitoxantrone is myelo-
suppression combined with cardiotoxicity.15,16 Encapsulation 
of mitoxantrone into PEGylated liposomes not only increases 
the tumor concentration of the drug via the permeability and 
retention effect but also decreases its biodistribution and, 
consequently, the toxicity associated with therapy.17–20
Several attempts have been made to improve the anticancer 
efficiency of liposomal mitoxantrone further by modifying 
it with vector molecules specific to receptors typical for 
cancerous cells. Folate-targeted liposomes loaded with 
mitoxantrone demonstrated a substantial increase in cytotox-
icity toward target cells in vitro.21 Similarly notable results 
were obtained with mitoxantrone-loaded liposomes com-
posed of anti-epidermal growth factor receptor monoclonal 
antibody fragments.22 Most of the vector molecules being 
investigated now are proteins (first of all, monoclonal 
antibodies) specific to only certain types of tumors. Some 
small peptide LHRH analogs among these molecules possess 
an ability to recognize a broad variety of tumors, but not 
normal cells. Targeting these small peptides has certain 
advantages, including ease of preparation, lower antigenicity, 
and increased stability over the use of conventional protein 
macromolecules. LHRH analog-modified nanocarriers 
have been used for the selective delivery of diagnostic or 
therapeutic agents to LHRH receptors overexpressing cancer 
cells. Its improved efficacy over nontargeted nanoparticles 
was also clearly evident in previous studies.23–25
We have developed a simple and efficient way to attach 
gonadorelin to the liposomal membrane. Procedures for the 
attachment of LHRH analogs to the liposome surface using 
electrostatic absorption or conventional coupling techniques 
have been previously reported.26,27 In these two approaches, 
the ligand was incorporated in the lipid bilayer during their 
formation which involves several steps and a considerable 
length of time, and leaves some reactive functional groups 
on the inner leaflet of the lipid bilayer. In our current work, 
an alternative design was used, whereby the ligand was 
first modified with an activated lipid derivative and then 
incorporated into liposomes by coincubating the micelles of 
peptide-PEG-DSPE with preformed liposomes. An advantage 
of this approach is that the preparation of liposomes and the 
modification of ligand are performed separately, allowing 
the selection of optimal conditions for each step. The 
resulting liposomes exhibited strong and selective binding 
ability to the LHRH receptor on overexpressing tumor cell 
lines, and subsequent internalization. Furthermore, when 
compared with generic drug-loaded liposomes, targeting led 
to a selective increase in cytotoxicity of the mitoxantrone-
loaded liposomes toward LHRH-receptor overexpressing 
tumor cell lines.
Materials and methods
Materials
A peptide analog of LHRH, gonadorelin (a synthetic human 
luteinizing hormone-releasing hormone), was purchased 
from ProSpec-Tany TechnoGene Ltd (Rehovot, Israel). 
The sequence of gonadorelin was Pyr-His-Trp-Ser-Tyr-
Gly-Leu-Arg-Pro-Gly-NH2 (molecular weight 1182.3). 
Mitoxantrone hydrochloride was obtained from Chongq-
ing Kailin Pharmaceutical Co., Ltd (Chongqing, China). 
Hydrogenated soybean phosphatidylcholine (HSPC) 
and [N-(carbonyl-methoxypolyethylene glycol 2000)-1, 
2-distearoyl-sn-  glycero-3-phosphoethanolamine sodium International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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salt] (mPEG2000-DSPE) were purchased from Lipoid 
(Ludwigshafen, Germany).   Cholesterol, 2-iminothiolane 
(Traut’s Reagent), 3-(4,5-dimethylthiazol-2-yl) 2, 
5-diphenyltetrazolium bromide (MTT), and Sephadex 
G10 were purchased from Sigma Chemical Co (St. Louis, 
MO). Maleimide-PEG2000-DSPE (Mal-PEG2000-DSPE) 
was purchased from Avanti Polar Lipids (Alabaster, AL). 
Phosphate-buffered saline (pH 7.4, 290 mosm) was pur-
chased from Tianjin Haoyang Biologicals Technology 
Co., Ltd (Tianjin, China). The bicinchoninic acid kit was 
purchased from Shanghai Shenergy Bicolor Bioscience 
and Technology Co (Shanhai, China). Ammonium sulfate 
and all other chemicals used in this study were of analyti-
cal grade or of high-performance liquid chromatography 
grade.
Cell line
Human MCF-7 breast cancer cells (LHRH receptor over-
expressing cancer cell line) and human ovarian cancer 
SK-OV-3 cells (LHRH receptor low-expressing cancer 
cell line) were purchased from the American Type Culture 
Collection (Manassas, VA). Cells were cultured in RPMI 
1640 medium (Sigma) supplemented with 10% fetal bovine 
serum (Tianjin Haoyang Biologicals Technology Co., Ltd). 
Cells were grown at 37°C in a humidified atmosphere of 5% 
CO2 (vol/vol) in air. All experiments were performed on cells 
during the exponential growth phase.
Preparation of PEGylated liposomes
Liposomes were prepared by lipid film hydration and 
ultrasonic dispersion. Briefly, the mixtures of HSPC, 
cholesterol, and mPEG2000-DSPE (molar ratio 90:10:0.4) 
were solubilized in chloroform and dried to a thin lipid film 
at 60°C, followed by incubation overnight under vacuum 
to remove residual solvent. The dried lipid films were 
subsequently hydrated with 300 mM ammonium sulfate 
at 60°C for one hour, and subjected to sonication (VCX-
130-PB; Sonics, Newtown, CT) for 10 minutes at 4°C (two 
minute pulses and two minutes of rest). This procedure 
formed small unilamellar vesicles. Small unilamellar vesicles 
were then centrifuged at 1000 g for 10 minutes to remove 
any titanium particles and larger aggregates. The particle 
size, polydispersity index, and zeta potential of the liposomes 
were determined by dynamic light scattering techniques (Zeta 
sizer Nano ZS; Malvern Instruments Ltd., UK) at 25°C and 
at a scattering angle of 90°. The obtained particle suspension 
was diluted appropriately in phosphate-buffered saline before 
measurement.
Preparation of thiolated gonadorelin  
and coupling procedure
Gonadorelin and Traut’s reagent were both dissolved in 
HEPES buffer (25 mM HEPES, 140 mM NaCl, pH 8.0) and 
mixed at a 1:4 molar ratio. This mixture was left to react for 
one hour, at room temperature, under dark conditions and 
under an inert N2 atmosphere. Unreacted Traut’s reagent 
was removed by size exclusion chromatography using a 
Sephadex G10 column with degassed HEPES buffer (pH 
8.0). Separately, the dried lipid films of Mal-PEG2000-DSPE 
were prehydrated at a concentration of 4 mg/mL in 
HEPES buffer (pH 8.0) at 60°C to form micelles. The 
thiolated-gonadorelin was then added to freshly prepared 
Mal-PEG2000-DSPE micelles at a 2:1 molar ratio. The 
resulting suspension was left to react overnight in the dark 
at room temperature with magnetic stirring under an inert 
N2 atmosphere. Free maleimide groups were quenched with 
an excess of histidine for 30 minutes at room temperature. 
Gonadorelin-coupled PEG-DSPE micelles were then con-
centrated in a Centriprep® Centrifugal filter, using a size 
cutoff of 3000 Da (Millipore, Billerica, MA). The amounts 
of conjugated and free gonadorelin were indirectly measured 
with a bicinchonic acid protein assay using pure bovine 
serum albumin as standard.30 The coupling efficiency of 
gonadorelin to Mal-PEG-DSPE was calculated as µg gona-
dorelin/µmol lipid.
Preparation of gonadorelin-modified 
liposomes
Gonadorelin-PEG-DSPE was then transferred into preformed 
PEGylated liposomes based on the procedure described 
previously.25,26 Briefly, the gonadorelin-PEG-DSPE solution 
was added to the preformed PEGylated liposome solution 
at 1:1000 gonadorelin-PEG-DSPE:phospholipid molar 
ratios and incubated at 60°C for one hour. The control 
PEGylated liposomes were prepared similarly by substituting 
gonadorelin-PEG-DSPE with mPEG2000-DSPE.
Transmembrane ammonium sulfate 
gradient loading of mitoxantrone
Mitoxantrone was encapsulated into the gonadorelin-modified 
or control PEGylated liposome formulations using transmem-
brane ammonium sulfate gradient-driven loading procedures. 
The procedure consisted of initially exchanging the buffer 
by dialysis for four hours against sucrose (300 mM)-histi-
dine (10 mM) buffer (pH 7.5), using dialysis tubing with 
a 10–12 kDa molecular weight cutoff (Pierce Chemical 
Co., Rockford, IL). Liposomes were incubated at 60°C for International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
700
He et al
10 minutes before addition of mitoxantrone, to achieve a final 
lipid to drug weight ratio of 10:1. The resulting mixture was 
incubated at 60°C for an additional 30 minutes, followed by 
dialysis against phosphate-buffered saline to remove the free 
mitoxantrone for determination of entrapment efficiency. The 
concentration of mitoxantrone was determined by measuring 
absorbance at 655 nm in a Varioskan Flash spectral scanning 
multimode reader (Thermo Scientific, Waltham, MA) after 
lysis of liposomes with 3% Triton-X 100.
In vitro drug release
Drug release experiments were performed in two different 
release buffers, (release buffer 1: phosphate-buffered saline 
at pH 7.4 and release buffer 2: 90% isotonic glucose solution 
buffered with 10 mM histidine to pH 7.5 and 10% human 
plasma). The liposomes were first diluted using the release 
media, to a HSPC concentration of 20 mM, and then 2 mL of 
diluted liposomes were put into dialysis tubing with a molecu-
lar weight cutoff of 10–12 kDa and dialyzed against 100 mL 
release buffers at 37°C. Each buffer contained 100 IU/mL 
penicillin and 100 µg/mL streptomycin.
At predetermined time intervals, samples were withdrawn 
from the release medium and assayed for mitoxantrone by 
high-performance liquid chromatography. Before analysis, 
samples containing plasma were extracted by protein 
precipitation,31 and samples without plasma were analyzed 
directly. Mitoxantrone was separated on a Zorbax SB C18 
column (150 mm × 4.6 mm, 5 µm, Agilent Technologies, 
Inc. Santa Clara, CA) at 35°C, and quantified by ultraviolet 
absorbance at 655 nm. The mobile phase consisted of 
acetonitrile and solutions containing 30 mM of sodium 
1-heptanesulfonate and 9.0 ml/L of glacial acetic acid (37:63, 
v/v) at a flow rate of 1 mL/min.
In vitro intracellular uptake of liposomal 
mitoxantrone
LHRH receptor overexpressing MCF-7 cells or LHRH 
receptor low-expressing SK-OV-3 cells were seeded 
at densities of 2 × 105 cm−2 in 35 mm diameter culture 
dishes and cultured in RPMI 1640 medium. After 24 hours 
of incubation, 50% confluency was reached and the 
medium was changed with 1 mL of fresh culture medium 
containing either gonadorelin-modified mitoxantrone-loaded 
liposomes (LHRH-MTX-SL) or nontarget mitoxantrone-
loaded liposomes (MTX-SL) at a dose of 0.2 mg total 
lipids (10 µg/mL as mitoxantrone) per dish. The cells were 
treated identically, except for the omission of reacting with 
mitoxantrone formulations was used as a negative control. 
After four hours of incubation at 37°C, the cells were washed 
three times with cold phosphate-buffered saline (pH 7.4) 
to remove unbound liposomes. The internalized liposomes 
were visualized using a confocal laser scanning microscope 
(Zeiss LSM 510, Germany), with excitation and emission 
wavelengths for mitoxantrone of 514 nm and 685 nm, 
respectively.
In vitro antitumor effect
A comparison of the cytotoxicity of free drug and vari-
ous liposomal formulations was performed on human 
MCF-7 cells by means of an in vitro proliferation assay using 
MTT. Briefly, 2 × 105 cells were seeded in 96-well plates and 
incubated overnight. Culture media with various concentra-
tions of free mitoxantrone or its liposomal formulations 
were then added in sextuplet, and incubation continued for 
an additional 24–120 hours. At designated time points, the 
medium was discarded and fresh medium containing MTT 
was added to each well. After four hours, the medium was 
removed, replaced with 100 µL methyl sulfoxide, and mixed 
on a vortex mixer for 10 minutes. Absorbance was recorded 
at 570 nm using the Varioskan Flash spectral scanning 
multimode reader. Cell viability was calculated as follows:
viability (%) = Atreated /Acontrol × 100%
IC50 was defined as the concentration of drug that reduced 
the optical density measured at 570 nm by 50% of the control 
value.
Statistical analyses
Statistical comparisons were carried out using one-way 
analysis of variance with SPSS 10.0 software (SPSS Inc., 
Chicago, IL). P values less than 0.05 were considered 
significant.
Results
Preparation and characterization  
of liposomal formulations
Gonadorelin-modified PEGylated liposomes were produced 
by transferring the conjugate of DSPE-PEG and gonadorelin 
from their loose micelles onto the liposome surface. Lipo-
somes consisted of small unilamellar vesicles containing 
HSPC, cholesterol, mPEG2000-DSPE, and Mal-PEG-DSPE 
for ligand conjugation. As controls, nontargeted PEGylated 
liposomes were prepared identically, except for the substi-
tution of mPEG2000-DSPE for gonadorelin-PEG-DSPE. 
Liposomes were then loaded with mitoxantrone using the International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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transmembrane ammonium sulfate gradient loading method 
(Figure 1). Up to 1.0 mg/mL of stable liposomal mitoxantrone 
loading was achieved, with approximately 98% of this being 
entrapped within the liposomes. The physical properties of 
the liposomes before and after coupling of gonadorelin are 
presented in Table 1. The size of the liposomes was in the 
range of 120–150 nm. The size of the gonadorelin-modified 
liposomes was found to be 15–20 nm larger than the origi-
nal liposome. The zeta potential was slightly lower after 
the ligand conjugation event due to the presence of peptides 
attached to the liposomal membrane via a longer PEG-linker. 
Regardless, the encapsulation of mitoxantrone did not signifi-
cantly affect the particle size of the liposome. The amount of 
gonadorelin in the liposome (assessed by bicinchoninic acid 
assay) in comparison with the amount of total phospholipids30 
are also presented in Table 1.
In vitro release of liposomal mitoxantrone
The in vitro release experiments were performed for 
quantitative comparison of the drug release characteristics of 
mitoxantrone from different mitoxantrone-loaded liposomal 
formulations. For all the formulations, the mitoxantrone/HSPC 
molar ratio and the entrapment ratio were similar. The drug 
release experiment was first performed in phosphate-buffered 
saline using a dialysis method. Under these conditions, the 
release should be attributed to “dilution effect”. As shown 
in Figure 2, both LHRH-MTX-SL and MTX-SL exhibited 
almost no release during the overall experimental period. The 
results clearly showed that dilution has little influence on the 
release of mitoxantrone from the liposomes.
The plasma-containing release buffer was also used to 
investigate the effect of plasma protein on mitoxantrone 
retention by liposomes. Because mitoxantrone has a strong 
affinity to some plasma proteins, protein binding might 
drive release of mitoxantrone from the vesicles. As shown 
in Figure 2, increased drug release of the two formulations 
was observed. After about 72 hours of incubation, more than 
8% mitoxantrone was released from both LHRH-MTX-SL 
and MTX-SL. Overall, the release experiments in different 
release media clearly showed the modification of liposomes 
with gonadorelin had no influence on the mitoxantrone 
retention.
Intracellular uptake of mitoxantrone 
formulations
To confirm LHRH receptor-mediated internalization of 
the gonadorelin-modified liposomes, the extent of cellular 
uptake of different liposomal formulations was evaluated by 
confocal laser scanning fluorescence microscopy in LHRH 
receptor overexpressing or low-expressing cell lines. The 
cells were incubated with either the MTX-SL or LHRH-
MTX-SL (10 µg/mL as mitoxantrone) at 37°C for four hours. 
Cells treated with drug-free medium were used as controls. 
In LHRH receptor overexpressing MCF-7 cells (Figures 3 A, 
3B, and 3C), incubation with LHRH-MTX-SL (Figure 3B) 
resulted in more extensive internalization and cytoplasmic 
accumulation than MTX-SL (Figure 3 A). In contrast, LHRH-
MTX-SL (Figure 3E) did not show improved uptake over 
MTX-SL (Figure 3D) in the LHRH low-expressing SK-OV-3 
cell type (Figures 3D, 3E, and 3F).
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Figure 1 Synthesis of LHRH-PEG-DSPE and preparation of LHRH-MTX-SL.
Abbreviations: LHRH, luteinizing hormone-releasing hormone; PEG, polyethylene glycol; MTX, mitoxanthrone; SL, loaded liposomes.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
702
He et al
In vitro antitumor effect
Comparison of the in vitro cytotoxicity of free mitoxantrone 
and mitoxantrone-loaded liposomal formulations was per-
formed using MCF-7 cells, which are known to overexpress 
the LHRH receptor. Cells were incubated with either free 
mitoxantrone or its liposomal formulations ranging from 
3 × 10−1 to 3 × 102 ng/mL for 24–120 hours. As shown in 
Figure 4, the empty liposomes exerted no effect on cell 
growth. Increasing the exposure time or drug concentration 
of either mitoxantrone or the mitoxantrone-loaded liposomal 
formulation led to improved efficacy, with the effects being 
more significant with the gonadorelin-modified liposome 
compared with the control nontargeted liposome.
The average in vitro IC50 values for free mitoxantrone, 
MTX-SL, and MTX-LHRH-SL from three parallel cytotoxic-
ity assays were 0.0445, 11.7, and 0.578 µg/mL, respectively 
(Table 2). Free mitoxantrone was significantly more cytotoxic 
than either MTX-SL or MTX-LHRH-SL after 120 hours 
of incubation (P , 0.05). Targeted formulations were sig-
nificantly more cytotoxic than nontargeted formulations 
(P , 0.05).
Discussion
In this study, we developed a simple yet highly efficient way 
to attach gonadorelin to liposomal membranes without com-
promising its specific activity or significantly affecting the 
amount or stability of the encapsulated drug. The LHRH ana-
log, gonadorelin, was coupled to end-functionalized groups 
in PEG-DSPE micelles, and then the gonadorelin-PEG-DSPE 
conjugates were transferred in a simple incubation step 
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Figure 2 Release profiles of mitoxantrone from MTX-SL and LHRH-MTX-SL in 
phosphate-buffered saline A or isotonic glucose containing 10% human plasma B 
Release of mitoxantrone from different liposome preparations was evaluated by a 
dialysis method, followed by high-performance liquid chromatography analysis for 
determination of mitoxantrone. Results are expressed as means ± standard error of 
measurement of three independent measurements.
Abbreviations: LHRH, luteinizing hormone-releasing hormone; MTX, mitoxanthrone; 
SL, loaded liposomes.
ABC
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Figure  3  Uptake  of  different  liposomes  encapsulating  mitoxantrone  in  various 
cell lines by confocal laser scanning fluorescence microscopy. Various cell lines 
were treated with either LHRH-MTX-SL or MTX-SL for four hours at 37°C. A 
LHRH-MTX-SL  in  LHRH  receptor  high-expressing  MCF-7  cells;  B  MTX-SL  in 
LHRH receptor high-expressing MCF-7 cells; C MCF-7 cells treated with drug-free 
medium used as a control; D LHRH-MTX-SL in LHRH receptor low-expressing 
SK-OV-3 cells; E MTX-SL in LHRH receptor low-expressing SK-OV-3 cells; F SK-
OV-3 cells treated with drug-free medium used as a control. 
Abbreviations: LHRH, luteinizing hormone-releasing hormone; MTX, mitoxanthrone; 
SL, loaded liposomes.
Table 1 Particle size, polydispersity index, zeta potential and gonadorelin:lipid ratio of liposomal formulations with or without 
mitoxantrone. The dynamic light scattering analysis was performed at 25°C and at a scattering angle of 90°. The obtained particle 
suspension was diluted appropriately in phosphate-buffered saline before measurement
Formulations MTX Particlesize (nm) PDI Zeta potential (mV) Gonadorelin: lipid ratio 
(μg/μmol)
Nontargeted 
liposome
With 124.7 ± 0.97 0.199 ± 0.012 −24.8 ± 0.62 –
Without 120.7 ± 0.95 0.157 ± 0.002 −25.3 ± 1.44 _
Targeted 
liposome
With 146.1 ± 0.94 0.280 ± 0.022 −14.4 ± 0.85 4.63 ± 0.09
Without 133.0 ± 1.12 0.243 ± 0.007 −18.2 ± 0.29 4.80 ± 0.12
Abbreviations: MTX, mitoxanthrone; PDI, polydispersity index.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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from the micelles into the outer monolayer of preformed 
liposomes. This method represents a combinatorial approach 
to the design of targeted liposomes that minimizes manu-
facturing complexities and allows a variety of ligands to be 
inserted into a variety of preformed liposomes containing a 
large range of drugs.32
The covalent coupling of thiolated gonadorelin to 
the maleimide terminus of DSPE- PEG was specifically 
explored. This methodology was chosen because the reaction 
between thiol and maleimide groups has been reported to be 
one of the most efficient reactions in bioconjugate chemistry, 
resulting in a stable thioether linkage.33
Moreira et al29 observed that insertion of peptide ligands 
into PEGylated liposomes may cause some membrane pertur-
bation, resulting in drug leakage from liposomes. Therefore, 
the loading of mitoxantrone was performed after insertion 
of the gonadorelin-PEG-DSPE conjugates. In these prepa-
rations, over 98% of drugs were entrapped within the lipo-
somes. Subsequently, mitoxantrone release was evaluated in 
different media (Figure 2). After 72 hours at 37°C, regardless 
of the incubation media, the drug release was approximately 
the same as that observed for control nontargeted liposomes, 
demonstrating that modification with gonadorelin had no 
influence on the membrane integrity of the liposomes.
Nonetheless, the liposomal formulations evaluated here 
exhibited sustained drug release characteristics. This find-
ing is in agreement with a previous report that indicated 
liposomal mitoxantrone was difficult to release from 
vesicles.34 This behavior is consistent with the presence of 
drug precipitates in the liposomal interior. After ammonium 
sulfate gradient-mediated uptake, mitoxantrone forms 
insoluble precipitates within the liposome. The permeability 
characteristics of the drug in a precipitated form may be less 
dependent on membrane characteristics or the collapse of the 
transmembrane ammonium gradient. The efflux rate of drugs 
is proportional to the concentration of the soluble form of 
the drug, which will remain constant until the precipitated 
form is dissolved. Thus, the time required for drug release 
should be proportional to the amount of drug present in the 
precipitated form.35,36
In the cell uptake test, gonadorelin-modified liposomes 
showed significantly higher uptake by their respective target 
cells in vitro, as compared with the control nontargeted 
liposomes, implying that the gonadorelin-modified liposome 
binds specifically to the LHRH receptor and is efficiently 
internalized by LHRH receptor-mediated endocytosis.37 
Endocytosis of the drug-liposome package into the cell 
interior would effectively limit the diffusion potential of the 
drug away from the target cell, which would in turn increase 
the amount of drug delivered to the target cell interior.
Using mitoxantrone-loaded, gonadorelin-modified 
liposomes, we showed that uptake by LHRH receptor 
overexpressing cells translates into increased cytotoxic-
ity, as compared with the drug-loaded control without the 
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Figure 4 Viability of MCF-7 cells after treatment with mitoxantrone, mitoxantrone-
containing liposomes, and empty liposomes for 24 hours A and 120 hours B The cells 
were exposed to serial concentrations of free mitoxantrone, MTX-SL, LHRH-MTX-
SL at 37°C for 24 hours or 120 hours. The drug concentration of free mitoxantrone 
and MTX-SL used in this assay was 0.3, 3.0, 30, 300 ng/mL. Empty liposomes were 
used as a control. The antitumor effect was evaluated usings the MTT method. 
MCF-7 cell viability (as a percentage of control cells) was calculated as follows: 
Viability(%) = Atreated/Acontrol × 100%. Results are expressed as means ± standard error 
of measurement from six independent measurements.
Table  2  Cytotoxicity  data  (IC50)  for  free  mitoxantrone  and 
mitoxantrone liposomal formulations (with or without LHRH) 
determined  with  MCF-7  cells  (n  =  3).  Data  are  represented 
as  percentage  of  control.  Each  assay  was  done  in  triplicate 
(mean  ±  standard  error  of  measurement).  The  cells  were 
exposed to serial concentrations of free mitoxantrone, MTX-
SL, and LHRH-MTX-SL at 37°C for 120 hours. The cytotoxicity 
was  evaluated  using  the  MTT  method.  MCF-7  cell  viability 
(as  a  percentage  of  control  cells)  was  calculated  as  follows: 
Viability  (%)  = A treated/Acontrol  ×  100%.  IC50  was  defined  as  the 
concentration of drug where cell growth and/or viability was 50% 
of that observed in control (drug-free) cultures in the MTT assay
Formulations IC50 (μg/mL)
Free MTX 0.0445 ± 0.0063
MTX-SL 11.7 ± 1.9
LHRH-MTX-SL 0.578 ± 0.014
Abbreviations: LHRH, luteinizing hormone-releasing hormone; MTX, mitoxanthrone; 
SL, loaded liposomes.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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gonadorelin-loaded liposome, probably due to distinct 
mechanisms of action. The cytotoxicity of MTX-SL is 
mainly owing to the gradual release of the encapsulated drug 
from liposomes close to the cell and uptake of the free drug 
into the target cell. The cytotoxicity of LHRH-MTX-SL 
may be attributed to receptor-mediated endocytosis of the 
liposomes, followed by slow breakdown of the liposomes 
in the cytoplasm and subsequent intracellular trafficking of 
the released drug. The empty gonadorelin-modified lipo-
somes were nontoxic, indicating that cytotoxicity was not 
mediated by the LHRH peptide displayed on the liposome   
surface.
Cytotoxicity of the LHRH-MTX-SL formulation used 
in this study did not reach that of the free drug. This is 
in accordance with previous studies for anti-epidermal 
growth factor receptor immunoliposomal formulations 
of mitoxantrone.22 Several factors may account for this 
observed discrepancy. For example, subcellular localiza-
tion of endocytosed immunoliposomes and the release 
rate of encapsulated drugs may all have profound influ-
ences on the efficiency of liposomal drugs.38 Endocytosed 
immunoliposomes are often routed through the endosomal 
and lysosomal pathways.39 For encapsulated mitoxantrone, 
release from liposomes and further escape from endosomes 
or lysosomes are required for translocation to the nucleus 
to effect disruption of DNA metabolism. In this study, the 
designed immunoliposomes exhibited sustained drug release 
characteristics. Moreover, the release rate of free drugs from 
the endosomes or lysosomes was also low, which depressed 
the action of mitoxantrone on tumor cells. Further develop-
ment of pH-sensitive liposome formulations may facilitate 
the collapse of liposomes, allowing more efficient release of 
encapsulated drug.40
Conclusions
The present study provides clear evidence that a simple 
immunomodification of mitoxantrone-loaded PEGylated 
liposomes with the LHRH analogs, Gonadorelin, against 
cancer-specific LHRH receptors results in successful devel-
opment of a rather universal tumor-targeted mitoxantrone 
delivery system. LHRH-MTX-SL significantly facilitated 
specific delivery of mitoxantrone to LHRH receptor over-
expressing tumor cells and efficiently inhibited tumor 
growth. This observation leads us to believe that LHRH-
MTX-SL has potential value for drug delivery therapy 
in future nanomedicine to treat human cancer and other   
diseases.
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